Tong Ren Tang Technologies Aktie - TNG

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,54

Gebot

0,515

Fragen

0,565

Volumen

0,00

0,00 Tagesbereich 0,00

0,545 52-Wochen-Bereich 0,795

Handelsende

0,555

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

10.400

Finanzvolumen

VWAP

INSERTING AND REPLACING: Transgene Reports 2013 Half Year Results

€72 million (above $90 million) in cash at end of June 2013 Important news-flow in Q4 for the two lead programs, TG4010 and Pexa-Vec...

Transgene Reports 2013 Half Year Results

€72 million (above $90 million) in cash at end of June 2013 Important news-flow in Q4 for the two lead programs, TG4010 and Pexa-Vec...

Transgene Announces that its Phase 2 study of Pexa-Vec in Second-line Advanced Liver Cancer did not Meet its Primary Endpoint

Conducting additional analyses of data, continuing to advance clinical trials in other cancers Announcing decision on Phase 3...

Transgene Grants Ascend Biopharmaceuticals a License to TG1042, an Immunotherapy to Treat Basal Cell Carcinoma, a Common Type...

Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy...

Transgene Announces the Nomination of Two New Board Members

Prof. Laurence Zitvogel (MD) and Mr Jean-Luc Bélingard were elected to the board at the AGM held on June 19, 2013

Transgene Announces that Platine Pharma Services, an Affiliate, is to Acquire Immuno-Monitoring Activities of Indicia Biotech...

Transaction will grow Platine Pharma Services’ business by 50% Transgene’s shareholding in Platine will be reduced to around 30%

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	-0.105	-16.2790697674	0.645	0.645	0.545	10400	0.58802885	DE
26	-0.05	-8.47457627119	0.59	0.66	0.545	11074	0.60003993	DE
52	-0.17	-23.9436619718	0.71	0.795	0.545	8341	0.62116191	DE
156	-0.225	-29.4117647059	0.765	0.8	0.545	5512	0.6372782	DE
260	-0.225	-29.4117647059	0.765	0.8	0.545	5512	0.6372782	DE

TNG - Frequently Asked Questions (FAQ)

What is the current Tong Ren Tang Technologies share price?

The current share price of Tong Ren Tang Technologies is 0,54 €

What is the 1 year trading range for Tong Ren Tang Technologies share price?

Tong Ren Tang Technologies has traded in the range of 0,545 € to 0,795 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WW6Ww International Inc	0,3468 € (169,88%)	144,1k
OYM1Odyssey Marine Exploration Inc	1,39 € (82,89%)	120,38k
VW5Cannabist Company Holdings Inc	0,0643 € (78,61%)	153,41k
Z620Trillion Energy International Inc	0,0307 € (48,31%)	103,45k
K8DWellfield Technologies Inc	0,0142 € (47,92%)	500
A07Avance Gas Holding Ltd	0,27 € (-46,80%)	1,26M
3SHShunfeng International Clean Energy Limited	0,0014 € (-36,36%)	3k
SQRSaia Inc.	216,00 € (-30,77%)	528
L7C2Windfall Geotek Inc	0,008 € (-30,43%)	32,29k
3PJ1Golden Dory Resourses	0,02 € (-25,93%)	40k
DMLSayona Mining Limited	0,0113 € (4,63%)	2,52M
11LCanopy Growth Corporation	1,222 € (-6,86%)	2,31M
PF8European Lithium Limited	0,0314 € (3,29%)	2,18M
D7GNel ASA	0,1982 € (-1,49%)	2,15M
3CPXiaomi Corporation	5,459 € (-1,83%)	1,56M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Tong Ren Tang Technologies Co (TNG)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

TNG Neueste Nachrichten

INSERTING AND REPLACING: Transgene Reports 2013 Half Year Results

Transgene Reports 2013 Half Year Results

Transgene Announces that its Phase 2 study of Pexa-Vec in Second-line Advanced Liver Cancer did not Meet its Primary Endpoint

Transgene Grants Ascend Biopharmaceuticals a License to TG1042, an Immunotherapy to Treat Basal Cell Carcinoma, a Common Type...

Transgene Announces the Nomination of Two New Board Members

Transgene Announces that Platine Pharma Services, an Affiliate, is to Acquire Immuno-Monitoring Activities of Indicia Biotech...

TNG - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Tong Ren Tang Technologies Co (TNG) Börsenkurse

Tong Ren Tang Technologies Co (TNG)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

TNG Neueste Nachrichten

INSERTING AND REPLACING: Transgene Reports 2013 Half Year Results

Transgene Reports 2013 Half Year Results

Transgene Announces that its Phase 2 study of Pexa-Vec in Second-line Advanced Liver Cancer did not Meet its Primary Endpoint

Transgene Grants Ascend Biopharmaceuticals a License to TG1042, an Immunotherapy to Treat Basal Cell Carcinoma, a Common Type...

Transgene Announces the Nomination of Two New Board Members

Transgene Announces that Platine Pharma Services, an Affiliate, is to Acquire Immuno-Monitoring Activities of Indicia Biotech...

TNG - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen